Research published by Purdue University indicates the possibility of slowing down or even halting Alzheimer’s. The research presents the SERCA activator as reducing cellular stress and preventing cell loss through the correction of calcium ions within the cell- this signifies a new frontier in therapeutic strategies for targeting neurodegenrative drug development.
Typically, brain cell loss occurs due to an imbalance in calcium ions, the research conducted aims to directly rectify this imbalance. The researchers developed molecules that target calcium handling proteins- in this case SERCA. Researcher’s focused on the role of the SERCA activator in neurodegenrative disorders. The aim of this study was primarily geared towards developing a drug that protects against cellular injury.
The evidence for the positive on Alzheimer’s is promising, the SERCA activator allowed for a 60% reduction in beta-amyloid plaques. The SERCA activator can also reverse apoptosis of cells, essentially reviving them from death. This is significant as the prevention of apoptosis can directly prevent neurodegeneration. This development is not only significant for treating Alzheimer’s but also other neurodegenrative diseases such as Parkinson’s and ALS.
Image taken from original study (2) demonstrating how the SERCA Activator may work.
1. https://www.sciencedaily.com/releases/2018/05/180510145916.htm – Original Article
2. https://www.sciencedirect.com/science/article/pii/S0960894X18302452 – Original Study